ストックスクリーナーアプリを入手
495.16
0.49%
-2.1144
前日終値:
$497.27
開ける：
$498.07
24時間の取引高:
137.88K
Relative Volume:
0.28
時価総額：
$21.23B
収益：
$3.17B
当期純損益:
$1.29B
株価収益率:
18.27
EPS:
27.0947
ネットキャッシュフロー:
$1.01B
1週間 パフォーマンス:
-0.46%
1か月 パフォーマンス:
-4.52%
6か月 パフォーマンス:
-6.70%
1年 パフォーマンス:
+20.73%
1日の値動き範囲:
$492.57
$499.23
1週間の範囲:
$492.57
$509.06
52週間の値動き範囲:
$408.75
$609.35
United Therapeutics Corp Stock (UTHR) Company Profile
名前
United Therapeutics Corp
セクター
電話
(301) 608-9292
住所
1000 SPRING ST, SILVER SPRING, MD
Compare UTHR vs TAK, TEVA, HLN, ZTS
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
UTHR
United Therapeutics Corp
|
495.04 | 21.32B | 3.17B | 1.29B | 1.01B | 27.09 |
TAK
Takeda Pharmaceutical Co Adr
|
18.94 | 58.31B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
38.77 | 43.22B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.245 | 40.41B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
72.69 | 30.15B | 9.51B | 2.64B | 2.14B | 6.0361 |
United Therapeutics Corp Stock (UTHR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-10 | 開始されました | Raymond James | Outperform |
| 2025-10-20 | 開始されました | Wells Fargo | Underweight |
| 2025-09-26 | 開始されました | RBC Capital Mkts | Outperform |
| 2025-06-02 | 開始されました | Cantor Fitzgerald | Overweight |
| 2025-04-25 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2025-04-21 | アップグレード | BofA Securities | Underperform → Neutral |
| 2024-07-11 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2024-02-12 | アップグレード | Goldman | Sell → Neutral |
| 2024-02-05 | 開始されました | Leerink Partners | Outperform |
| 2023-12-08 | 開始されました | Wells Fargo | Overweight |
| 2022-12-06 | 開始されました | UBS | Buy |
| 2022-12-05 | 開始されました | Goldman | Sell |
| 2022-10-11 | 開始されました | Morgan Stanley | Overweight |
| 2022-09-20 | 繰り返されました | BofA Securities | Underperform |
| 2022-09-19 | 再開されました | Wedbush | Outperform |
| 2022-02-11 | 開始されました | BTIG Research | Neutral |
| 2021-07-14 | アップグレード | Argus | Hold → Buy |
| 2021-04-26 | 再開されました | Credit Suisse | Outperform |
| 2021-02-01 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2020-09-14 | 再開されました | JP Morgan | Overweight |
| 2020-06-25 | 繰り返されました | H.C. Wainwright | Neutral |
| 2020-03-10 | アップグレード | Jefferies | Hold → Buy |
| 2020-02-27 | アップグレード | Cowen | Market Perform → Outperform |
| 2020-01-31 | アップグレード | JP Morgan | Neutral → Overweight |
| 2019-12-03 | 開始されました | BofA/Merrill | Underperform |
| 2019-08-01 | アップグレード | Jefferies | Underperform → Hold |
| 2019-08-01 | アップグレード | Ladenburg Thalmann | Neutral → Buy |
| 2019-07-01 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2019-05-17 | アップグレード | UBS | Sell → Neutral |
| 2019-05-09 | アップグレード | Credit Suisse | Underperform → Neutral |
| 2018-10-12 | アップグレード | Standpoint Research | Hold → Buy |
| 2018-08-08 | ダウングレード | Credit Suisse | Neutral → Underperform |
| 2018-04-03 | アップグレード | Credit Suisse | Underperform → Neutral |
| 2018-02-22 | 繰り返されました | Barclays | Underweight |
| 2018-01-18 | 再開されました | Credit Suisse | Underperform |
| 2017-12-27 | 繰り返されました | Wedbush | Outperform |
| 2017-04-27 | 繰り返されました | Wedbush | Outperform |
| 2017-03-30 | 開始されました | UBS | Sell |
| 2017-03-16 | 開始されました | Credit Suisse | Underperform |
すべてを表示
United Therapeutics Corp (UTHR) 最新ニュース
United Therapeutics (UTHR) CEO exercises options, sells 9,500 shares - Stock Titan
LQDA Loses 13.9% in a Month: Should Investors Avoid the Stock Now? - Zacks Investment Research
United Therapeutics (UTHR) Sets $477.6 Million Buyback. Can Pipeline Funding Keep Pace? - Yahoo Finance
United Therapeutics (UTHR) CEO sells 9,500 shares under 10b5-1 plan - Stock Titan
United Therapeutics CEO Martine Rothblatt sells $4.7m in stock By Investing.com - Investing.com Australia
United Therapeutics at Cantor healthcare conference: fibrosis push widens By Investing.com - Investing.com Australia
United Therapeutics CEO Martine Rothblatt sells $4.7m in stock - investing.com
United Therapeutics (UTHR) CEO exercises options and sells 9,500 shares in preset plan - Stock Titan
United Therapeutics Launches $477.6M Accelerated Share Buyback - Minichart
United Therapeutics Launches $477.6 Million Accelerated Share Repurchase With Citi - TradingView
United Therapeutics (UTHR) moves to return $4B to shareholders with new buyback - Stock Titan
United Therapeutics (UTHR) CEO sells 9,500 shares under preset trading plan - Stock Titan
United Therapeutics Corporation at Wells Fargo Healthcare Conference Transcript - GuruFocus
United Therapeutics Corporation Announces Accelerated Share Repurchase Agreement for Remainder of $2.0 Billion Authorization - marketscreener.com
United Therapeutics Corporation (UTHR) Stock Analysis: Insights on a 36.24% Potential Upside - DirectorsTalk Interviews
United Therapeutics (NASDAQ: UTHR) CEO sells 9,500 shares under 10b5-1 plan - Stock Titan
MannKind Stock Plummets After Partner United Therapeutics Unveils New ‘Category Killer Product’ - Stocktwits
United Therapeutics (UTHR) Down 8% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Anheuser-Busch plant in Merrimack sold to United Therapeutics for $47.5M - UnionLeader.com
United Therapeutics EVP Paul A. Mahon Executes Stock Option Exercise and Sells Shares Under 10b5-1 Plan - kalkinemedia.com
United Therapeutics (UTHR) counsel sells 8,300 shares under preset plan - Stock Titan
United Therapeutics (UTHR) CEO offloads 9,500 shares in planned trade - Stock Titan
United Therapeutics (NASDAQ:UTHR) Offers Growth At A Fair Price - Kalkine Media
United Therapeutics (NASDAQ:UTHR) Fits the Growth-at-a-Reasonable-Price Model - ChartMill
Merrimack’s Anheuser-Busch property sold for $47m - The Cabinet Press
United Therapeutics Corp (UTHR) Stock Down 4.1% but Still Overva - GuruFocus
United Therapeutics (UTHR) CEO sells 9,500 shares under trading plan - Stock Titan
United Therapeutics Slides as Investors Weigh Insider Selling Against a New Regulatory Milestone - Quiver Quantitative
United Therapeutics FDA Accepts Tyvaso IPF Filing | UTHR Stock News - stocktitan.net
United Therapeutics (UTHR) CEO sells more shares under preset trading plan - Stock Titan
Stewartville's xenotransplant pig facility is ready for animals - Post Bulletin
Four healthcare conferences will host United Therapeutics executives in September. The talks will be streamed live. - Stock Titan
United Therapeutics (UTHR) CEO sells 9,500 shares under preset plan - Stock Titan
United Therapeutics Corporation (UTHR) Stock Analysis: Evaluating a 28.88% Upside Potential in the Healthcare Sector - DirectorsTalk Interviews
United Therapeutics (UTHR) CEO sells shares via preset options plan - Stock Titan
United Therapeutics to present drug trial data at conferences - Investing.com
United Therapeutics will present data showing improved lung function in idiopathic pulmonary fibrosis - Stock Titan
FDA Accepts United Therapeutics' NDA Filing for Ralinepag in PAH - Yahoo Finance
United Therapeutics (NASDAQ: UTHR) CEO sells 9,500 shares in preset plan - Stock Titan
United Therapeutics (NASDAQ: UTHR) CEO sells 9,500 under 10b5-1 plan - Stock Titan
United Therapeutics Ralinepag NDA Accepted by FDA With June 2027 Decision Date - Yahoo Finance
United Therapeutics (NASDAQ: UTHR) CEO sale part of 1,734,410-option 10b5-1 plan - Stock Titan
United Therapeutics (UTHR) legal chief sells 8,300 shares - Stock Titan
United Therapeutics (NASDAQ: UTHR) CEO trades under 1,734,410-option 10b5-1 plan - Stock Titan
United Therapeutics (NASDAQ:UTHR) Stands Out as a Quality Stock with Durable Profitability and Strong Returns - ChartMill
ETFs Investing in United Therapeutics Corporation Stocks - TradingView
United Therapeutics (UTHR) CEO sells shares under preset trading plan - Stock Titan
United Therapeutics (NASDAQ: UTHR) CEO sells 9,500 shares - Stock Titan
United Therapeutics (UTHR) Q2 2026 Earnings Call Transcript - AOL.com
United Therapeutics Completes Enrollment in Phase 3 PPF Trial of Tyvaso - marketscreener.com
United Therapeutics completes enrollment in lung fibrosis trial - Investing.com
United Therapeutics Corp (UTHR) 財務データ
収益
当期純利益
現金流量
EPS
United Therapeutics Corp (UTHR) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| ROTHBLATT MARTINE A | Chairperson & CEO |
Sep 16 '26 |
Sale |
501.39 |
9,500 |
4,763,172 |
324,443 |
0.67%
大文字化:
|
ボリューム (24 時間):